Literature DB >> 24402133

Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.

Kenichi Fukumoto1, Michihiko Iijima, Shigeyuki Chaki.   

Abstract

RATIONALE: α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor stimulation has been proposed to be a common neural mechanism of metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists and an N-methyl-D-aspartate receptor antagonist, ketamine, exerting antidepressant effects in animal models. AMPA receptor stimulation has also been shown to mediate an increase in the extracellular level of serotonin (5-HT) in the medial prefrontal cortex by an mGlu2/3 receptor antagonist in rats. However, involvement of the serotonergic system in the actions of mGlu2/3 receptor antagonists and ketamine is not well understood.
OBJECTIVES: We investigated involvement of the serotonergic system in the effects of an mGlu2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and ketamine in a novelty-suppressed feeding (NSF) test in mice.
RESULTS: The intraperitoneal administration of LY341495 or ketamine at 30 min prior to the test significantly shortened latency to feed, which was attenuated by an AMPA receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydr-obenzo[f]quinoxaline-7-sulfonamide (NBQX). The effects of LY341495 and ketamine were no longer observed in mice pretreated with a tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA). Moreover, the effects of LY341495 and ketamine were blocked by a 5-HT1A receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-carboxamide (WAY100635), but not by a 5-HT2A/2C receptor antagonist, ritanserin. Likewise, an AMPA receptor potentiator, 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone (CX546), shortened latency to feed in the NSF test, which was prevented by depletion of 5-HT and blockade of 5-HT1A receptor.
CONCLUSIONS: These results suggest that AMPA receptor-dependent 5-HT release and subsequent 5-HT1A receptor stimulation may be involved in the actions of an mGlu2/3 receptor antagonist and ketamine in the NSF test.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402133     DOI: 10.1007/s00213-013-3378-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

2.  Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors.

Authors:  Naoya Kawashima; Jun-ichi Karasawa; Toshiharu Shimazaki; Shigeyuki Chaki; Shigeru Okuyama; Akito Yasuhara; Atsuro Nakazato
Journal:  Neurosci Lett       Date:  2005-01-05       Impact factor: 3.046

3.  Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice.

Authors:  Michihiko Iijima; Toshiharu Shimazaki; Akie Ito; Shigeyuki Chaki
Journal:  Psychopharmacology (Berl)       Date:  2006-11-11       Impact factor: 4.530

4.  Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

Authors:  Lobna Ibrahim; Nancy Diazgranados; David A Luckenbaugh; Rodrigo Machado-Vieira; Jacqueline Baumann; Alan G Mallinger; Carlos A Zarate
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-04-03       Impact factor: 5.067

5.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Authors:  G J Marek; R A Wright; D D Schoepp; J A Monn; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

6.  Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.

Authors:  Hiroyuki Koike; Kenichi Fukumoto; Michihiko Iijima; Shigeyuki Chaki
Journal:  Behav Brain Res       Date:  2012-10-23       Impact factor: 3.332

7.  Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.

Authors:  K Stachowicz; K Gołembiowska; M Sowa; G Nowak; E Chojnacka-Wójcik; A Pilc
Journal:  Neuropharmacology       Date:  2007-08-14       Impact factor: 5.250

8.  Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.

Authors:  G P Luscombe; K F Martin; L J Hutchins; J Gosden; D J Heal
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

10.  Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex.

Authors:  Yukio Ago; Yutaka Koyama; Akemichi Baba; Toshio Matsuda
Journal:  Neuropharmacology       Date:  2003-12       Impact factor: 5.250

View more
  30 in total

1.  The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.

Authors:  Kenichi Fukumoto; Michihiko Iijima; Shigeyuki Chaki
Journal:  Neuropsychopharmacology       Date:  2015-08-06       Impact factor: 7.853

2.  cGMP-dependent protein kinase type II knockout mice exhibit working memory impairments, decreased repetitive behavior, and increased anxiety-like traits.

Authors:  Charlotte M Wincott; Sinedu Abera; Sarah A Vunck; Natasha Tirko; Yoon Choi; Roseann F Titcombe; Shannon O Antoine; David S Tukey; Loren M DeVito; Franz Hofmann; Charles A Hoeffer; Edward B Ziff
Journal:  Neurobiol Learn Mem       Date:  2014-04-18       Impact factor: 2.877

3.  Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.

Authors:  Brendan D Hare; Santosh Pothula; Ralph J DiLeone; Ronald S Duman
Journal:  Neuropharmacology       Date:  2020-01-09       Impact factor: 5.250

Review 4.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 6.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 7.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

8.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

9.  Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation.

Authors:  Kenichi Fukumoto; Manoela V Fogaça; Rong-Jian Liu; Catharine H Duman; Xiao-Yuan Li; Shigeyuki Chaki; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2020-05-12       Impact factor: 7.853

Review 10.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.